Akers Biosciences Signs Agreement to Sell METRON(R) Breath Ketone Test Online, With Key Focus on Amazon Marketplace
May 06 2015 - 7:00AM
Akers Biosciences, Inc. (Nasdaq:AKER) (AIM:AKR.L), ("Akers Bio" or
the "Company"), a medical device company focused on reducing the
cost of healthcare through faster, easier diagnostics, has
appointed InstaNatural, LLC., (the "Reseller") as its online
marketing partner to build consumer awareness and preference, with
exclusive rights for Amazon representation, for the Company's
consumer-focused METRON® breath ketone test, aimed at the health
and wellness market.
The METRON® breath ketone test is the only disposable
breath-based diagnostic device that rapidly determines if the
subject is in the optimal fat-burning state for weight loss, known
as ketosis. Achieving a state of ketosis is a goal of many
individuals following low carbohydrate diets. METRON®, based on the
Company's proprietary MPC Biosensor technology, uses a simple,
non-invasive process to identify in minutes whether ketones present
in exhaled breath are at a level indicative of ketosis.
"Ketosis is a state at which the body has an extremely high
fat-burning rate," said Raymond F. Akers, Jr. PhD, Co-founder and
Executive Chairman of the Board. "It is therefore an essential
metabolic state for endurance athletes and anybody who is serious
about losing weight."
"We have seen significant consumer interest in the METRON®
breath ketone test since the Company announced its development
because of its simplicity and accuracy when compared to existing
urine or blood-based tests. We are very excited to be making it
available later this year online, with a focus on Amazon, which is
the largest U.S. online retailer," continued Dr. Akers. "Our
strategic partners are experts in online product positioning and
new product launches and will be initially targeting the
weight-loss market, as well as endurance athletes."
"It is an honor to be chosen by Akers Bio to bring their
proprietary, game-changing diagnostic to the online consumer,"
Aditya Patel, President of InstaNatural, LLC added. "We are
enthusiastic about the potential of this partnership and for the
power it brings to improve the health and wellness of consumers
following ketogenic (low-carb) diets."
The Reseller intends to employ dedicated and specially trained
personnel to promote online sales and to support the growth of the
customer base.
The Agreement will automatically renew for one year at each
anniversary, provided the Reseller achieves certain contractual
milestones.
ABOUT AKERS BIOSCIENCES, INC.
Akers Biosciences develops, manufactures, and supplies rapid
screening and testing products designed to deliver quicker and more
cost-effective healthcare information to healthcare providers and
consumers. The Company has advanced the science of diagnostics
while responding to major shifts in healthcare through the
development of several proprietary platform technologies. The
Company's state-of-the-art rapid diagnostic assays can be performed
virtually anywhere in minutes when time is of the essence. The
Company has aligned with major healthcare companies and high volume
medical product distributors to maximize product offerings, and to
be a major worldwide competitor in diagnostics.
Additional information on the Company and its products can be
found at www.akersbiosciences.com. Follow us on Twitter
@AkersBio.
Cautionary Statement Regarding Forward Looking
Statements
Statements contained herein that are not based upon current or
historical fact are forward-looking in nature and constitute
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934. Such forward-looking statements reflect the Company's
expectations about its future operating results, performance and
opportunities that involve substantial risks and uncertainties.
These statements include but are not limited to statements
regarding the intended terms of the offering, closing of the
offering and use of any proceeds from the offering. When used
herein, the words "anticipate," "believe," "estimate," "upcoming,"
"plan," "target", "intend" and "expect" and similar expressions, as
they relate to Akers Biosciences, Inc., its subsidiaries, or its
management, are intended to identify such forward-looking
statements. These forward-looking statements are based on
information currently available to the Company and are subject to a
number of risks, uncertainties, and other factors that could cause
the Company's actual results, performance, prospects, and
opportunities to differ materially from those expressed in, or
implied by, these forward-looking statements.
CONTACT: For more information:
Akers Biosciences, Inc.
Raymond F. Akers, Jr. PhD
Executive Chairman of the Board
Tel. +1 856 848 8698
finnCap (UK Nominated Adviser and Broker)
Geoff Nash / Scott Mathieson (Corporate Finance)
Steve Norcross (Broking)
Tel. +44 (0) 20 7220 0500
Taglich Brothers, Inc. (US Investor Relations)
Chris Schreiber
Tel. +1 917 445 6207
Vigo Communications (UK Investor Relations)
Ben Simons / Fiona Henson
Tel. +44 (0) 20 7016 9570
Email: akers@vigocomms.com
Akers Biosciences (NASDAQ:AKER)
Historical Stock Chart
From Jul 2024 to Aug 2024
Akers Biosciences (NASDAQ:AKER)
Historical Stock Chart
From Aug 2023 to Aug 2024